GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
GSK plc (GLAXF) - Total Assets
Latest total assets as of December 2025: $61.11 Billion USD
Based on the latest financial reports, GSK plc (GLAXF) holds total assets worth $61.11 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GSK plc - Total Assets Trend (1985–2025)
This chart illustrates how GSK plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GSK plc - Asset Composition Analysis
Current Asset Composition (December 2025)
GSK plc's total assets of $61.11 Billion consist of 28.7% current assets and 71.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.6% |
| Accounts Receivable | $7.76 Billion | 12.7% |
| Inventory | $5.92 Billion | 9.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.75 Billion | 27.4% |
| Goodwill | $7.02 Billion | 11.5% |
Asset Composition Trend (1985–2025)
This chart illustrates how GSK plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GSK plc's current assets represent 28.7% of total assets in 2025, a decrease from 67.7% in 1985.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, up from 1.9% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 27.4% of total assets.
GSK plc Competitors by Total Assets
Key competitors of GSK plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
GSK plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - GSK plc generates 0.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, GSK plc generates $9.35 in net profit.
GSK plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.78 | 0.91 |
| Quick Ratio | 0.54 | 0.52 | 0.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.88 Billion | $ -4.70 Billion | $ -1.75 Billion |
GSK plc - Advanced Valuation Insights
This section examines the relationship between GSK plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | $61.11 Billion |
| Market Capitalization | $71.18 Billion USD |
Valuation Analysis
Above Book Valuation: The market values GSK plc's assets above their book value (1.16 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: GSK plc's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GSK plc (1985–2025)
The table below shows the annual total assets of GSK plc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.11 Billion | +2.77% |
| 2024-12-31 | $59.46 Billion | +0.78% |
| 2023-12-31 | $59.01 Billion | -1.90% |
| 2022-12-31 | $60.15 Billion | -23.96% |
| 2021-12-31 | $79.10 Billion | -1.65% |
| 2020-12-31 | $80.43 Billion | +0.93% |
| 2019-12-31 | $79.69 Billion | +37.24% |
| 2018-12-31 | $58.07 Billion | +2.99% |
| 2017-12-31 | $56.38 Billion | -4.57% |
| 2016-12-31 | $59.08 Billion | +10.54% |
| 2015-12-31 | $53.45 Billion | +31.48% |
| 2014-12-31 | $40.65 Billion | -3.41% |
| 2013-12-31 | $42.09 Billion | +1.47% |
| 2012-12-31 | $41.48 Billion | +0.96% |
| 2011-12-31 | $41.08 Billion | -2.31% |
| 2010-12-31 | $42.05 Billion | -1.89% |
| 2009-12-31 | $42.86 Billion | +8.81% |
| 2008-12-31 | $39.39 Billion | +27.06% |
| 2007-12-31 | $31.00 Billion | +21.33% |
| 2006-12-31 | $25.55 Billion | -6.05% |
| 2005-12-31 | $27.20 Billion | +18.54% |
| 2004-12-31 | $22.94 Billion | -4.18% |
| 2003-12-31 | $23.94 Billion | +7.24% |
| 2002-12-31 | $22.33 Billion | +1.65% |
| 2001-12-31 | $21.97 Billion | +1.74% |
| 2000-12-31 | $21.59 Billion | +107.06% |
| 1999-12-31 | $10.43 Billion | +11.57% |
| 1998-12-31 | $9.35 Billion | +10.77% |
| 1997-12-31 | $8.44 Billion | +1.48% |
| 1996-12-31 | $8.31 Billion | -2.66% |
| 1995-12-31 | $8.54 Billion | +8.29% |
| 1993-12-31 | $7.89 Billion | +5.75% |
| 1992-12-31 | $7.46 Billion | +31.26% |
| 1991-12-31 | $5.68 Billion | -1.08% |
| 1990-12-31 | $5.74 Billion | +27.87% |
| 1989-12-31 | $4.49 Billion | +29.49% |
| 1988-12-31 | $3.47 Billion | +21.00% |
| 1987-12-31 | $2.87 Billion | +21.59% |
| 1986-12-31 | $2.36 Billion | +30.78% |
| 1985-12-31 | $1.80 Billion | -- |